The Classic Egg-Yolk Macular Dystrophy of Childhood
There's a moment in candle-making where melted wax, poured into a mould, sits smooth and whole before it slowly begins to crack and settle as it cools and shifts. Best disease follows a comparable arc beneath the macula — a rounded, yellow deposit that starts out smooth and intact, gradually breaks apart over a period of years, and eventually settles into its final resting form. The name vitelliform comes from the Latin for egg yolk, describing exactly what that deposit looks like at its outset, and it is this staged journey, more than any single symptom, that shapes how the disease is followed over time.
One detail regularly surprises Tanzanian families at their first consultation: a child can carry a strikingly visible yolk-shaped lesion on examination and still read comfortably at their expected level. The lesion's appearance and a person's actual vision simply don't always move together, which is exactly why correctly staging the disease matters far more than reacting to how dramatic the retinal photograph looks.
In the earliest, intact stage, central vision is often only mildly affected — sometimes not affected at all — even though the lesion itself is unmistakable on examination. Symptoms tend to appear once the once-smooth deposit begins breaking apart, a stage often described as resembling a scrambled egg; this is typically when blurred or distorted central vision, along with difficulty with fine print, first becomes noticeable. As the disease reaches its later, more settled stages, central vision loss tends to become more entrenched, and for a smaller share of patients, abnormal blood vessels developing beneath the retina can cause an additional, sudden drop on top of that.
A fault in the BEST1 gene lies behind this condition, a gene that ordinarily produces a protein called bestrophin-1 responsible for regulating ion and fluid movement across the retinal pigment epithelium. Once that regulation breaks down, fluid and pigment gather abnormally beneath the macula and slowly take the shape of the lesion seen on examination. It is inherited as a dominant trait, though how strongly it shows up varies a great deal — some carriers show a clearly visible lesion with barely any symptoms, while others in the same family face more meaningful changes to their vision.
An electro-oculogram carries most of the diagnostic weight here, since it typically comes back sharply abnormal — a low Arden ratio — even in an eye whose plain ERG trace looks entirely unremarkable, and it's that particular gap between the two results that points a specialist toward Best disease rather than a lesion that merely looks similar. Repeat OCT imaging across successive visits charts how the deposit is progressing through its stages, and a confirmed BEST1 mutation both settles the diagnosis and flags which relatives might be quietly carrying the gene.
Given how long this lesion can remain unchanged, our early approach favours careful, staged observation over immediate intervention, with particular attention paid to the modest but real chance of abnormal vessel growth as the lesion continues its slow evolution. Once a patient's vision has genuinely begun to suffer, regenerative stem cell therapy enters the discussion as part of a plan built around holding onto whatever central function is still there.
Yes, and it's actually one of the more reassuring, well-recognised patterns in the early stage of Best disease. A lesion's size on a photograph doesn't directly predict how well someone actually sees, which is exactly why proper staging matters far more than the dramatic appearance of the image alone.
No — it stays a self-contained, benign condition confined entirely to the retina, with no connection to cancer of any kind. It does move through a series of recognised stages over time, though, and tracking that progression is precisely the purpose of our ongoing monitoring.
That comes down to variable expressivity, a well-documented feature of BEST1 mutations. He could easily carry the very same faulty gene without it ever producing a visible lesion or symptoms — testing him directly is the only way to know for certain rather than assuming he's been spared.
Not everyone — a good number of patients hold onto reasonably strong central vision for many years, particularly those whose lesion doesn't progress past its earlier stages. Because that course genuinely differs from one person to the next, ongoing monitoring is what lets us respond quickly the moment something does shift.